Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 7 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMASSISTANCE from Geel, company number BE0449618655, closed financial year 2025 with a result of € -1,501 after tax. For that financial year PHARMASSISTANCE recorded a gross margin of € 11,393 and equity of € -368,433. Compared with financial year 2024, the result moved from € -6,803 to € -1,501. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ -368,433
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,501
▲ 78 % less loss than in 2024
Profit after tax over the fiscal year.
€ 1,177
▲ 76% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -473,433.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
€ 54,962
Loans from banks and other lenders, long and short.
€ 5,761
▼ 6% vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 588 | € 11,157 | € 6,782 | € 11,393 | ▲ 68% |
| Profit after taxes | € -7,177 | € -2,267 | € -6,803 | € -1,501 | ▲ € 5,302 |
| Equity | € -357,862 | € -360,129 | € -366,932 | € -368,433 | |
| Total debts | € 371,867 | € 384,355 | € 389,482 | € 397,327 | ▲ 2% |
| Cash | € 364 | € 767 | € 670 | € 1,177 | ▲ 76% |
| Retained profit | € -462,862 | € -465,129 | € -471,932 | € -473,433 | |
| Bank debt | € 54,962 | € 54,962 | € 54,962 | € 54,962 | |
| Balance sheet total | € 14,005 | € 24,226 | € 22,549 | € 28,893 | ▲ 28% |
Key figures of PHARMASSISTANCE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMASSISTANCE?
What happened at PHARMASSISTANCE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1,501. Source: NBB ↗
- New establishment in Geel. KBO
- Start of the company according to the CBE. KBO
In short
From € 7,177 loss in 2022 to € 1,501 loss in 2025.
Management
Behind PHARMASSISTANCE are Kristien Vanhoucke and Mediphar Invest NV NV. Kristien Vanhoucke is also behind Mediphar Invest and Oogkliniek Dr. K. Vanhoucke.
Directors
According to the 2025 annual accounts
Director · represented by Boeckx Jozef Frans
Establishments
Establishment units
Physical locations of this company
Doornboomstraat 5 box A
2440 Geel
Doornboomstraat 5 box a
2440 Geel
Active since 24 March 1993
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0449.618.655
- VAT number
- BE 0449.618.655
- Registered office
- Doornboomstraat 5 bus A, 2440 Geel
- Names & denominations
- PHARMASSISTANCE
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 March 1993
- Peppol
- Active · Active since 26 Sept 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering